LAVA Therapeutics Discontinues Development of LAVA-1207, Jan. 20, 2025
LAVA Therapeutics has discontinued the development of LAVA-1207, a bispecific gamma-delta T-cell engager for PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), after Phase 1/2a trial data failed to meet internal benchmarks. The company will focus on advancing its pipeline, including LAVA-1266 for acute myeloid leukemia and myelodysplastic syndrome. With $79 million in cash, LAVA expects funding to support operations through 2027.
Full Article: LAVA Therapeutics Development Update
NANOBIOTIX Doses First Patient in Phase 2 Study for Non-Small Cell Lung Cancer, Jan. 21, 2025
NANOBIOTIX has announced the dosing of the first patient in the Phase 2 CONVERGE study, evaluating JNJ-1900 (NBTXR3), a first-in-class radioenhancer for Stage 3 unresectable non-small cell lung cancer receiving chemoradiation and durvalumab consolidation. The study is sponsored by Janssen Pharmaceutica NV under a global license agreement.
Full Article: NANOBIOTIX Clinical Trial Update
NiKang Therapeutics Doses First Patient in Phase 1b/2 Study for Hepatocellular Carcinoma, Jan. 21, 2025
NiKang Therapeutics has announced the first patient dosed in a global Phase 1b/2 study evaluating NKT2152, a potent HIF2α inhibitor, in combination with atezolizumab and bevacizumab for advanced hepatocellular carcinoma. This milestone highlights NKT2152’s potential in expanding combination therapies in solid tumors.
Full Article: NiKang Therapeutics Clinical Trial Update
Kiromic BioPharma Reports Tumor Reduction in Deltacel-01 Trial, Jan. 21, 2025
Kiromic BioPharma has announced promising results from its Deltacel-01 Phase 1 trial evaluating Deltacel (KB-GDT-01), an allogeneic Gamma Delta T-cell therapy for advanced NSCLC. The first patient showed a 33.33% tumor reduction at 12 months, while the seventh patient demonstrated a 9.5% reduction at two months.
Full Article: Kiromic BioPharma Trial Data
Novocure Opens New Global Headquarters in Zug, Jan. 22, 2025
Novocure has officially opened its new global headquarters in Baar, Canton of Zug, Switzerland. The state-of-the-art facility reflects Novocure's commitment to sustainability and collaboration, advancing its Tumor Treating Fields (TTFields) therapy for cancer treatment. The move aligns with Novocure’s 25th year of innovation.
Full Article: Novocure Company Update
Ymmunobio Secures Innosuisse Grant for YB-800 Platform, Jan. 23, 2025
Ymmunobio, in collaboration with the Paul Scherrer Institute, has received an Innosuisse grant to develop radiolabeled antibodies for treating and diagnosing solid tumors. This collaboration advances Ymmunobio’s preclinical programs and aims to address unmet needs in gastrointestinal cancers.
Full Article: Ymmunobio Partnership Update
Biogen Announces Research Workforce Reductions, Jan. 23, 2025
Biogen has announced layoffs in its research unit as part of a broader cost-cutting strategy to streamline operations and accelerate drug discovery. This decision comes alongside the positive news of Spinraza’s higher-dose regimen being accepted for regulatory review.
Full Article: Biogen Workforce Update
Rakuten Medical Launches Phase 3 Trial for ASP-1929 in Head and Neck Cancer, Jan. 23, 2025
Rakuten Medical has initiated a global Phase 3 trial (ECLIPSE) to evaluate ASP-1929 photoimmunotherapy combined with pembrolizumab for first-line recurrent head and neck squamous cell carcinoma. The study aims to assess overall survival as the primary endpoint.
Full Article: Rakuten Medical Clinical Trial Update
Genprex Doses First Patient in Acclaim-3 Study for Small Cell Lung Cancer, Jan. 23, 2025
Genprex has dosed the first patient in the Phase 2 expansion of the Acclaim-3 study, evaluating Reqorsa Gene Therapy in combination with Tecentriq for extensive-stage small cell lung cancer. The trial aims to assess progression-free survival rates.
Full Article: Genprex Clinical Trial Update
Merck’s Keytruda Combo Fails to Extend Survival in GI Cancer Trial, Jan. 24, 2025
Merck and Eisai's Keytruda-Lenvima combination failed to meet the overall survival endpoint in the Phase III LEAP-015 trial for advanced gastroesophageal adenocarcinoma. Despite showing improvements in progression-free survival, the trial highlights the challenges of treating these cancers.
Full Article: Merck Trial Results
